← All trials
NCT07181135
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- Dec 31, 2027
- Completion date
- Dec 31, 2027
- First posted
- Sep 18, 2025
- Last posted
- Sep 24, 2025
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of GroningenLead sponsor
- University of GroningenOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.